Chemistry:Tunlametinib
From HandWiki
Tunlametinib is a pharmaceutical drug for the treatment of cancer. It is an inhbitor of mitogen-activated protein kinase kinase.[1]
In China, tunlametinib was approved in 2024 for the treatment of patients with NRAS-mutated advanced melanoma who were previously treated with a PD-1/PD-L1 targeting agent.[2][3]
It is also being studied for use in combination with vemurafenib in patients with advanced BRAF V600-mutant solid tumors.[4]
References
- ↑ "Tunlametinib". NCI Drug Dictionary. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tunlametinib.
- ↑ "Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy". March 18, 2024. https://www.onclive.com/view/tunlametinib-wins-approval-in-china-for-nras-advanced-melanoma-after-pd-1-pd-l1-therapy.
- ↑ Keam, Susan J. (2024). "Tunlametinib: First Approval". Drugs 84 (8): 1005–1010. doi:10.1007/s40265-024-02072-x. PMID 39034326. https://figshare.com/articles/online_resource/Tunlametinib_First_Approval/26103526.
- ↑ Shi, Yuankai; Han, Xiaohong; Zhao, Qian; Zheng, Yulong; Chen, Jianhua; Yu, Xinmin; Fang, Jian; Liu, Yutao et al. (2024). "Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: An open-label, single-arm, multicenter, phase I study". Experimental Hematology & Oncology 13 (1): 60. doi:10.1186/s40164-024-00528-0. PMID 38867257.
 |  |
